Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland

K Schumann; C Mauch; KC Klespe; C Loquai; U Nikfarjam; M Schlaak; L Akcetin; P Kolblinger; M Hoellwerth; M Meissner; G Mengi; AD Braun; M Mengoni; R Dummer; J Mangana; MA Sindrilaru; D Radmann; C Hafner; J Freund; K Rappersberger; F Weihsengruber; F Meiss; L Reinhardt; F Meier; B Rainer; E Richtig; JM Ressler; C Holler; T Eigentler; T Amaral; WK Peitsch; U Hillen; W Harth; F Ziller; K Schatton; T Gambichler; L Susok; LV Maul; H Laubli; Dirk Debus; C Weishaupt; S Borger; K Sievers; S Haferkamp; V Zenderowski; V Nguyen; M Wanner; R Gutzmer; P Terheyden; K Kahler; S Emmert; A Thiem; M Sachse; S Gercken-Riedel; KM Kaune; KM Thoms; L Heinzerling; MV Heppt; S Tratzmiller; W Hoetzenecker; A Ollinger; A Steiner; T Peinhaupt; M Podda; S Schmid; U Wollina; T Biedermann; C Posch

doi:10.1111/jdv.18779

Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland

K Schumann
, C Mauch
, KC Klespe
, C Loquai
, U Nikfarjam
, M Schlaak
, L Akcetin
, P Kolblinger (Co-author)
, M Hoellwerth (Co-author)
, M Meissner
, G Mengi
, AD Braun
, M Mengoni
, R Dummer
, J Mangana
, MA Sindrilaru
, D Radmann
, C Hafner
, J Freund
, K Rappersberger

F Weihsengruber, F Meiss, L Reinhardt, F Meier, B Rainer, E Richtig, JM Ressler, C Holler, T Eigentler, T Amaral, WK Peitsch, U Hillen, W Harth, F Ziller, K Schatton, T Gambichler, L Susok, LV Maul, H Laubli, Dirk Debus (Co-author), C Weishaupt, S Borger, K Sievers, S Haferkamp, V Zenderowski, V Nguyen, M Wanner, R Gutzmer, P Terheyden, K Kahler, S Emmert, A Thiem, M Sachse, S Gercken-Riedel, KM Kaune, KM Thoms, L Heinzerling, MV Heppt, S Tratzmiller, W Hoetzenecker, A Ollinger, A Steiner, T Peinhaupt, M Podda, S Schmid, U Wollina, T Biedermann, C Posch

Research output: Contribution to journal › Original Article › peer-review

27 Citations (Web of Science)

Original language	English
Pages (from-to)	894-906
Number of pages	13
Journal	JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
Volume	37
Issue number	5
Early online date	12 Dec 2022
DOIs	https://doi.org/10.1111/jdv.18779
Publication status	Published - May 2023

Keywords

STAGE-III
MULTICENTER
IPILIMUMAB
NIVOLUMAB
Melanoma/pathology
Melanoma, Cutaneous Malignant
Humans
Proto-Oncogene Proteins B-raf/genetics
Mitogen-Activated Protein Kinase Kinases/therapeutic use
Antineoplastic Combined Chemotherapy Protocols/adverse effects
Switzerland
Skin Neoplasms/pathology
Austria
Adjuvants, Immunologic/therapeutic use
Retrospective Studies

Access to Document

10.1111/jdv.18779

Cite this

Schumann, K., Mauch, C., Klespe, KC., Loquai, C., Nikfarjam, U., Schlaak, M., Akcetin, L., Kolblinger, P., Hoellwerth, M., Meissner, M., Mengi, G., Braun, AD., Mengoni, M., Dummer, R., Mangana, J., Sindrilaru, MA., Radmann, D., Hafner, C., Freund, J., ... Posch, C. (2023). Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY , 37(5), 894-906. https://doi.org/10.1111/jdv.18779

Schumann, K ; Mauch, C ; Klespe, KC et al. / Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland. In: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY 2023 ; Vol. 37, No. 5. pp. 894-906.

@article{e974a8bb984446f1927a01a401f40a05,

title = "Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland",

keywords = "STAGE-III, MULTICENTER, IPILIMUMAB, NIVOLUMAB, Melanoma/pathology, Melanoma, Cutaneous Malignant, Humans, Proto-Oncogene Proteins B-raf/genetics, Mitogen-Activated Protein Kinase Kinases/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Switzerland, Skin Neoplasms/pathology, Austria, Adjuvants, Immunologic/therapeutic use, Retrospective Studies",

author = "K Schumann and C Mauch and KC Klespe and C Loquai and U Nikfarjam and M Schlaak and L Akcetin and P Kolblinger and M Hoellwerth and M Meissner and G Mengi and AD Braun and M Mengoni and R Dummer and J Mangana and MA Sindrilaru and D Radmann and C Hafner and J Freund and K Rappersberger and F Weihsengruber and F Meiss and L Reinhardt and F Meier and B Rainer and E Richtig and JM Ressler and C Holler and T Eigentler and T Amaral and WK Peitsch and U Hillen and W Harth and F Ziller and K Schatton and T Gambichler and L Susok and LV Maul and H Laubli and Dirk Debus and C Weishaupt and S Borger and K Sievers and S Haferkamp and V Zenderowski and V Nguyen and M Wanner and R Gutzmer and P Terheyden and K Kahler and S Emmert and A Thiem and M Sachse and S Gercken-Riedel and KM Kaune and KM Thoms and L Heinzerling and MV Heppt and S Tratzmiller and W Hoetzenecker and A Ollinger and A Steiner and T Peinhaupt and M Podda and S Schmid and U Wollina and T Biedermann and C Posch",

note = "Debus: Department of Dermatology, Nuremberg General Hospital – Paracelsus Medical University, Nuremberg, Germany; K{\"o}lblinger, H{\"o}llwerth: Department for Dermatology and Allergology, Paracelsus Medical University, Salzburg, Austria {\textcopyright} 2022 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley \& Sons Ltd on behalf of European Academy of Dermatology and Venereology.",

year = "2023",

month = may,

doi = "10.1111/jdv.18779",

language = "English",

volume = "37",

pages = "894--906",

journal = "JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY ",

issn = "0926-9959",

publisher = "Wiley Verlag ",

number = "5",

}

Schumann, K, Mauch, C, Klespe, KC, Loquai, C, Nikfarjam, U, Schlaak, M, Akcetin, L, Kolblinger, P , Hoellwerth, M, Meissner, M, Mengi, G, Braun, AD, Mengoni, M, Dummer, R, Mangana, J, Sindrilaru, MA, Radmann, D, Hafner, C, Freund, J, Rappersberger, K, Weihsengruber, F, Meiss, F, Reinhardt, L, Meier, F, Rainer, B, Richtig, E, Ressler, JM, Holler, C, Eigentler, T, Amaral, T, Peitsch, WK, Hillen, U, Harth, W, Ziller, F, Schatton, K, Gambichler, T, Susok, L, Maul, LV, Laubli, H, Debus, D, Weishaupt, C, Borger, S, Sievers, K, Haferkamp, S, Zenderowski, V, Nguyen, V, Wanner, M, Gutzmer, R, Terheyden, P, Kahler, K, Emmert, S, Thiem, A, Sachse, M, Gercken-Riedel, S, Kaune, KM, Thoms, KM, Heinzerling, L, Heppt, MV, Tratzmiller, S, Hoetzenecker, W, Ollinger, A, Steiner, A, Peinhaupt, T, Podda, M, Schmid, S, Wollina, U, Biedermann, T & Posch, C 2023, 'Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland', JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY , vol. 37, no. 5, pp. 894-906. https://doi.org/10.1111/jdv.18779

Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland. / Schumann, K; Mauch, C; Klespe, KC et al.
In: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY , Vol. 37, No. 5, 05.2023, p. 894-906.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland

AU - Schumann, K

AU - Mauch, C

AU - Klespe, KC

AU - Loquai, C

AU - Nikfarjam, U

AU - Schlaak, M

AU - Akcetin, L

AU - Kolblinger, P

AU - Hoellwerth, M

AU - Meissner, M

AU - Mengi, G

AU - Braun, AD

AU - Mengoni, M

AU - Dummer, R

AU - Mangana, J

AU - Sindrilaru, MA

AU - Radmann, D

AU - Hafner, C

AU - Freund, J

AU - Rappersberger, K

AU - Weihsengruber, F

AU - Meiss, F

AU - Reinhardt, L

AU - Meier, F

AU - Rainer, B

AU - Richtig, E

AU - Ressler, JM

AU - Holler, C

AU - Eigentler, T

AU - Amaral, T

AU - Peitsch, WK

AU - Hillen, U

AU - Harth, W

AU - Ziller, F

AU - Schatton, K

AU - Gambichler, T

AU - Susok, L

AU - Maul, LV

AU - Laubli, H

AU - Debus, Dirk

AU - Weishaupt, C

AU - Borger, S

AU - Sievers, K

AU - Haferkamp, S

AU - Zenderowski, V

AU - Nguyen, V

AU - Wanner, M

AU - Gutzmer, R

AU - Terheyden, P

AU - Kahler, K

AU - Emmert, S

AU - Thiem, A

AU - Sachse, M

AU - Gercken-Riedel, S

AU - Kaune, KM

AU - Thoms, KM

AU - Heinzerling, L

AU - Heppt, MV

AU - Tratzmiller, S

AU - Hoetzenecker, W

AU - Ollinger, A

AU - Steiner, A

AU - Peinhaupt, T

AU - Podda, M

AU - Schmid, S

AU - Wollina, U

AU - Biedermann, T

AU - Posch, C

N1 - Debus: Department of Dermatology, Nuremberg General Hospital – Paracelsus Medical University, Nuremberg, Germany; Kölblinger, Höllwerth: Department for Dermatology and Allergology, Paracelsus Medical University, Salzburg, Austria © 2022 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.

PY - 2023/5

Y1 - 2023/5

KW - STAGE-III

KW - MULTICENTER

KW - IPILIMUMAB

KW - NIVOLUMAB

KW - Melanoma/pathology

KW - Melanoma, Cutaneous Malignant

KW - Humans

KW - Proto-Oncogene Proteins B-raf/genetics

KW - Mitogen-Activated Protein Kinase Kinases/therapeutic use

KW - Antineoplastic Combined Chemotherapy Protocols/adverse effects

KW - Switzerland

KW - Skin Neoplasms/pathology

KW - Austria

KW - Adjuvants, Immunologic/therapeutic use

KW - Retrospective Studies

U2 - 10.1111/jdv.18779

DO - 10.1111/jdv.18779

M3 - Original Article

C2 - 36433688

SN - 0926-9959

VL - 37

SP - 894

EP - 906

JO - JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

JF - JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

IS - 5

ER -

Schumann K, Mauch C, Klespe KC, Loquai C, Nikfarjam U, Schlaak M et al. Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY . 2023 May;37(5):894-906. Epub 2022 Dec 12. doi: 10.1111/jdv.18779